Resources
22 Results (showing 1 - 10)
Results sorted by posted date (newest first)
Results sorted by posted date (newest first)
Posted 8/25/2023 (updated 3/26/2024)
As HIV transmission via injection drugs are increasing, knowing the variation in which the the transmission occurs can be beneficial in treatment and intervention. Authors of the study look into the frequency and distribution of HIV transmission behaviors among people who use drugs in rural areas to possibly determine if interventions could be universally effective. Data collected in the study suggests that there are many variations in the transmission behaviors.
Posted 6/18/2023 (updated 3/28/2024)
This report provides information on the results of the Cherokee Nation Health Services' (CNHS) hepatitis C elimination program 5 years after implementation. The report finds that the program had success with 99% of patients who completed treatment.
Posted 10/12/2022 (updated 3/27/2024)
Monday, October 3rd was Child Health Day 2022, an observance and recommitment to the health and well-being of children and their families.
Posted 1/25/2022 (updated 3/26/2024)
RCORP-TA is pleased to provide technical assistance resources related to grantee business operations that we have prepared for grantees. RCORP-TA is providing these resources to assist grantees on aspects of their business operations that are continuously impacted and routinely challenged by factors associated with living and working in rural communities. Please see the below linked guidance documents and descriptions as they may be of interest to you.
Posted 7/28/2021 (updated 4/2/2024)
Various state and local jurisdictions in the United States are implementing mobile models for treating opioid use disorder (OUD). In August 2020, RTI International spoke with six agencies to learn more about their mobile treatment programs. This article is the first in a three-part series on mobile response programs and provides an in-depth look at two of these programs. We will discuss the remaining programs in two subsequent articles. The goal of this series is to inform jurisdictions considering whether a mobile treatment program would work in their communities and to determine what type of model would fit best.
Posted 4/21/2021 (updated 4/5/2024)
This News Brief defines psychostimulants; explains why psychostimulant use disorder is under-addressed, particularly in rural areas; reviews the reasons why people use psychostimulants and the harms they can cause; and addresses the impact of COVID-19 on psychostimulant use.
Posted 3/6/2021 (updated 4/5/2024)
HepVu released new interactive maps visualizing U.S. county-level Hepatitis C-related mortality, illustrating how factors such as age and geographic region affect health outcomes. Published in Hepatology, the data demonstrate that Hepatitis C-related mortality has been decreasing across the U.S. since 2013
Posted 3/1/2021 (updated 4/4/2024)
o CAST (calculating for an adequate system tool) produces community-specific assessments of the capacity of the components of a community substance abuse care system. CAST generates recommendations by the application of social and community determinants of health as risk coefficients to each estimate of component need. CAST can assist public health practitioners in evaluation and improvement of the capacity of community-based, substance abuse care systems.
Posted 11/11/2020 (updated 4/3/2024)
This report describes decedent demographic characteristics and circumstances surrounding overdose deaths during January–June 2019 among 25 jurisdictions participating in CDC’s State Unintentional Drug Overdose Reporting System (SUDORS),† and it highlights the involvement of opioids and stimulants, separately and in combination.
Posted 11/10/2020 (updated 4/3/2024)
In the context of the trends in Oregon SUD metrics and the increasing infectious complications related to IDU in other jurisdictions and their implications for HIV and HCV transmission, we sought to 1) describe statewide trends in IDU-related serious bacterial infections (SBI) hospitalizations overall and by SBI type and drug use diagnosis, 2) assess IDU-related SBI diagnoses among individuals living with HIV and HCV, and 3) and determine the annual costs of IDU-related SBI overall and by SBI type.